Collectively we suggest that FYN by activating STAT5 signaling plays an important role in FLT3-ITD-mediated transformation in AML and therefore a combinatorial therapy targeting FYN in addition to FLT3-ITD would likely be beneficial for this group of patients. Here, FLT3 is linked to acute myeloid leukemia.